<SEC-DOCUMENT>0001628280-23-038899.txt : 20231114
<SEC-HEADER>0001628280-23-038899.hdr.sgml : 20231114
<ACCEPTANCE-DATETIME>20231114153934
ACCESSION NUMBER:		0001628280-23-038899
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231114
FILED AS OF DATE:		20231114
DATE AS OF CHANGE:		20231114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		231405291

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk11x14x2023.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2881cd2eb0464640ab18079c57279a35_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the month of November, 2023.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">November 14, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="cybinpressrelease-closingf.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated November 14, 2023</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cybinpressrelease-closingf.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9c763aca473d4ee68893f133a0dbccdf_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.77pt;padding-right:5.77pt;text-align:center;text-indent:0.25pt"><font style="color:#070707;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><img alt="image_0.jpg" src="image_0.jpg" style="height:143px;margin-bottom:5pt;vertical-align:text-bottom;width:247px"><font style="color:#070707;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">  &#160;&#160;&#160;&#160;</font></div><div style="padding-left:5.77pt;padding-right:5.77pt;text-align:center;text-indent:0.25pt"><font><br></font></div><div style="padding-left:5.77pt;padding-right:5.77pt;text-align:center;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CYBIN ANNOUNCES CLOSING OF OFFERING OF UNITS LED BY ONE OF THE COMPANY&#8217;S LARGEST INSTITUTIONAL SHAREHOLDERS </font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211; November 14, 2023 &#8211; Cybin Inc. (NYSE American&#58;CYBN) (NEO&#58;CYBN) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cybin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that it has closed its previously announced underwritten offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). In connection with the Offering, the Company issued an aggregate of 66,666,667 units of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at a price of US$0.45 per Unit for aggregate gross proceeds of US$30 million.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Unit is comprised of one common share in the capital of the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and one Common Share purchase warrant (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Each Warrant is exercisable to acquire one Common Share at a price of US$0.51 per Common Share any time on or after the date that is six months after issuance until May 14, 2029, subject to acceleration in certain circumstances.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Q4 of 2023 and 2024 will be pivotal for Cybin as we expect topline clinical data readouts from both our Phase 1&#47;2a trial of CYB003, our deuterated psilocybin analog, and from our Phase 1 trial of CYB004 and SPL028, our deuterated DMT programs. With the current financing, led by one of the Company&#8217;s largest institutional shareholders, and a combination of the Company's current cash position, current at-the-market offering and assuming exercise in full of the Warrants issued as part of the Units, the Company has access to over US$100 million. This capital is expected to provide Cybin with the cash runway needed to complete these value-driving clinical milestones and enable us to continue focusing on clinical execution with the ultimate goal of bringing improved therapeutic options to patients in need,&#8221; said Doug Drysdale, Chief Executive Officer of Cybin.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.G.P.&#47;Alliance Global Partners acted as the sole book-running manager for the Offering.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company intends to use the net proceeds from the Offering for the progression of the Company&#8217;s CYB003 and deuterated DMT programs, and for general corporate and working capital purposes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Units were offered pursuant to a prospectus supplement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the Company&#8217;s short form base shelf prospectus dated August 17, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Base Shelf Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that was filed with the Ontario Securities Commission. The Prospectus Supplement was also filed with the United States Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as part of a registration statement on Form F-10, as amended, which became effective by the SEC on August 17, 2023 in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. The Prospectus Supplement, Base Shelf Prospectus and the documents incorporated by reference therein are available on the Company&#8217;s SEDAR profile at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.sedarplus.ca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the Company&#8217;s EDGAR profile at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov&#47;edgar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Copies of the Prospectus Supplement and Base Shelf Prospectus may be obtained by contacting </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.G.P.&#47;Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">prospectus&#64;allianceg.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.</font></div><div style="margin-top:12.6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Cybin</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cautionary Notes and Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain statements in this press release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (together, &#8220;forward-looking statements&#8221;). All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin&#8217;s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;aim&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;would&#8221;, &#8220;anticipate&#8221;, &#8220;estimate&#8221;, &#8220;forecast&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;seek&#8221;, &#8220;should&#8221; or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the use of Offering proceeds&#59; the Company&#8217;s plan to report topline clinical data readouts from the Phase 1&#47;2a trial of CYB003 and from the Phase 1 trial of CYB004 and SPL028 in Q4&#59; the Company&#8217;s ability to access capital under its current at-the-market offering&#59; the Company&#8217;s ability to access capital as a result of the exercise of the Warrants&#59; and the Company&#8217;s ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include&#58; implications of the COVID-19 pandemic on the Company&#8217;s operations&#59; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the psychedelics market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; and the risk factors set out in the Company's management's discussion and analysis for the three months ended June 30, 2023, the Company&#8217;s annual information form for the year ended March 31, 2023, and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on www.sedarplus.ca and with the SEC on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cybin makes no medical, treatment or health benefit claims about Cybin&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#8217;s performance and operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor &#38; Media Contact</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gabriel Fahel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Legal Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cybin Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1-866-292-4601</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">irteam&#64;cybin.com &#8211; or &#8211; media&#64;cybin.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
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MUA-03XX":SN09@>'+3:W9VXIKZRY(!#%Q/CTV#+<PG?;EQ+Z_2B;IH<!5V5
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MR(::8<-QYGF_\$' X<![0&L3!Z%,V[T*7-PZO(>.HP6 2[\#:TA'JS,7J+Q
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M51V2+6^=7X_A4@1"5WAMPK CAQQQER"29E55OHME$-9Z#0L%"\%RG#3U^(I
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M.F!Y1EZRV!-6+IYWG*9(\\':HF$4/7H&MFWK5!+FC+[@@K9 W#68[M]_8N'
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MA0HT<$Q6T1.KO+/L<9+$[X0,\Z^&97R_K++F5Y73YQ2T#7!%>0H4[3K\GJ[
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M.N<@)DHK%%G^,JXIWA94PNVZ\:9C\V/'3ZI[/Q#']&_HS)DSP?'*W_/J,I:
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=CB6,B8D$(?\?A/Z1E48]>=8     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
